BeOne Medicines (NASDAQ:ONC) Shares Down 5.4% - Here's What Happened

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) shares traded down 5.4% on Tuesday . The company traded as low as $249.52 and last traded at $250.13. 83,899 shares were traded during trading, a decline of 81% from the average session volume of 446,589 shares. The stock had previously closed at $264.42.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Guggenheim lifted their target price on shares of BeOne Medicines from $348.00 to $350.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Royal Bank Of Canada lowered their target price on shares of BeOne Medicines from $312.00 to $311.00 and set an "outperform" rating on the stock in a research note on Thursday, May 8th. Macquarie lifted their target price on shares of BeOne Medicines from $259.00 to $313.00 and gave the company an "outperform" rating in a research note on Friday, February 28th. Wall Street Zen upgraded shares of BeOne Medicines from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. Finally, Bank of America upgraded shares of BeOne Medicines from a "neutral" rating to a "buy" rating and lifted their price target for the company from $207.00 to $320.00 in a report on Monday, March 3rd. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $319.00.

BeOne Medicines Stock Performance

The company has a quick ratio of 1.71, a current ratio of 1.96 and a debt-to-equity ratio of 0.05. The company has a market cap of $27.07 billion, a P/E ratio of -66.42 and a beta of 0.30. The stock's fifty day simple moving average is $245.59.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $1.22 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.71) by $1.93. BeOne Medicines had a negative net margin of 9.40% and a negative return on equity of 7.55%. The company had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.12 billion. As a group, analysts forecast that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 EPS for the current year.

Insider Transactions at BeOne Medicines

In other news, CEO John Oyler sold 1,460 shares of the business's stock in a transaction dated Tuesday, June 17th. The shares were sold at an average price of $256.49, for a total value of $374,475.40. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Xiaobin Wu sold 51,921 shares of the business's stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $281.40, for a total transaction of $14,610,569.40. The disclosure for this sale can be found here. Insiders have sold a total of 195,880 shares of company stock worth $49,871,511 in the last three months. Insiders own 6.62% of the company's stock.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.